Erlotinib (Tarceva®, OSI Pharmaceutical) is a type-I EGFR inhibitor analogous to gefitinib, yet more potent and less selective, which is efficient in similar mutation-positive NSCLC patients (EGFR Kd = 0.67 nM) [27,66]. Here, EGFR is linked to non-small cell lung carcinoma.